Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma

Cancer Science

Volumn 105, Issue 3, 2014, Pages 354-358

  Hagihara, Atsushi ^a,b   Ikeda, Masafumi ^c   Ueno, Hideki ^a   Morizane, Chigusa ^a   Kondo, Shunsuke ^a   Nakachi, Kohei ^c   Mitsunaga, Shuichi ^c   Shimizu, Satoshi ^c   Kojima, Yasushi ^c   Suzuki, Eiichiro ^c   Katayama, Kazuhiro ^d   Imanaka, Kazuho ^d   Tamai, Chie ^d   Inaba, Yoshitaka ^e   Sato, Yozo ^e   Kato, Mina ^e   Okusaka, Takuji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Arterial infusion; Chemotherapy; Cisplatin; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; SORAFENIB; TRIACYLGLYCEROL LIPASE;

ABLATION THERAPY; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; INTRAARTERIAL DRUG ADMINISTRATION; LEUKOPENIA; LIVER CELL CARCINOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TRANSCATHETER ARTERIAL INFUSION; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR GROWTH; YOUNG ADULT;

ARTERIAL INFUSION; CHEMOTHERAPY; CISPLATIN; HEPATOCELLULAR CARCINOMA; SORAFENIB;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DISEASE-FREE SURVIVAL; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84895562141     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12353     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399): 1907-17.
3. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
5. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
7. Ensminger WD, Gyves JW. Regional chemotherapy of neoplastic diseases. Pharmacol Ther 1983; 21: 277-93.
8. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 1122-5.
9. Court WS, Order SE, Siegel JA et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002; 20: 613-25.
10. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008; 38: 474-83.
11. Okuda K, Tanaka M, Shibata J et al. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6: 587-91.
12. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
13. Lencioni R, Kudo M, Ye SL et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2013. doi: 10.1111/ijcp.12352. [Epub ahead of print].
14. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-65.
15. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-60.
16. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993; 50(1): 22-6.
17. Heim M, Scharifi M, Zisowsky J et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 2005; 16: 129-36.
18. Chen FS, Cui YZ, Luo RC, Wu J, Zhang H. Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 1684-7.
19. Wei Y, Shen N, Wang Z et al. Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/beta-catenin signaling. Mol Cell Biochem 2013; 381: 139-44.
20. Schmid I, Haberle B, Albert MH et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012; 58: 539-44.
21. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28: 2947-51.
22. Kim C, Lee JL, Choi YH et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2012; 30: 306-15.
23. Yamada Y, Kiyota N, Fuse N et al. A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric Cancer 2014; 17: 161-72.
24. Davies JM, Dhruva NS, Walko CM et al. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer 2011; 71: 151-5.
25. Paz-Ares LG, Biesma B, Heigener D et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30: 3084-92.
26. Xue C, Huang Y, Huang PY et al. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 2013; 24: 1055-61.
27. Schultheis B, Kummer G, Zeth M et al. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemother Pharmacol 2012; 69: 333-9.
28. Ikeda M, Okusaka T, Furuse J et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol 2013; 72: 463-70.